Related Experiment Video
Updated: Apr 3, 2026
08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
17.6K
Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism
Tammy Hennika1, Oren J Becher2
1Department of Pediatrics Duke University Medical Center, Durham, NC, USA Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Journal of Child Neurology
|September 17, 2015
Summary
Diffuse intrinsic pontine glioma (DIPG) is a deadly childhood brain cancer with poor survival rates. New genetic discoveries offer hope for targeted therapies beyond current radiation treatments.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Cancer genomics
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive and lethal pediatric brain tumor originating in the pons.
- Current standard treatment, focal radiation therapy, offers only transient palliation with a median survival of less than one year.
- Over three decades, there has been no significant improvement in survival rates for DIPG patients.
Observation:
- Recent genomic studies have identified specific mutations in DIPG tumors.
- K27M H3.3/H3.1 mutations are found in 80% of DIPG cases.
- ACVR1 mutations are present in 25% of diffuse intrinsic pontine gliomas.
Findings:
- The discovery of K27M and ACVR1 mutations provides crucial molecular targets for therapeutic development.
- Stereotactic tumor biopsies are safe and increasingly utilized in diagnostic protocols.
- Biopsies are now integrated into prospective clinical trials for DIPG.
Implications:
- These genetic findings open new avenues for developing targeted therapies against DIPG.
- Improved diagnostic strategies, including safe biopsy procedures, enhance patient stratification for clinical trials.
- Future research directions focus on leveraging molecular insights for novel, effective treatments for this devastating childhood cancer.
